EXSIGHT VENTURES
  • Home
  • Companies
  • Team
  • Blog
  • Contact
  • Thesis

DR. RAHHAL ADDS "HOST" TO HIS MANY TALENTS:  INTRODUCING THE OIS RETINA PODCAST

7/11/2020

0 Comments

 
Picture
ExSight founding partner, Dr. Firas Rahhal, is no stranger to the OIS stage and has even had a turn as host of OIS TV. Firas discusses this new role below.

It has been an honor and a privilege to be invited to host the new OIS-Retina Podcast.  The OIS has become one of the best and most important meetings in Ophthalmology over the last decade or so.  I have been attending regularly, along with my partners at ExSight Ventures, since 2014, and have become a more active participant in the last few years.  It is the meeting place for innovators, industry professionals, clinical scientists, clinicians, and investors.  There is no other meeting with this great constellation of professionals in the field of ophthalmology. 

So the OIS-Retina Podcast seeks to mimic this unique offering of information, discussion, education, and possibly debate, in the form of small group dialogue or interview between myself and many of the individual stakeholders in this space.  Of course, given the name of the Podcast itself and my particular clinical expertise, many of the discussions will revolve around the posterior segment of the eye, but will certainly not be exclusively so.

I will attempt to have a mixture of guests from all parties in the previously mentioned fields, namely the innovators/founders, the CEOs and CMOs of the “small” start-up companies, the upper management personnel from the “big” corporations, as well as individuals from leading investment groups.  With my busy clinical vitreoretinal surgery practice (Retina Vitreous Associates in LA), significant involvement in clinical trials, and role at ExSight Ventures as a background and hopefully lending some context, I will ask questions probing all aspects of the innovation and development process. Topics will range from first de novo ideas in the lab, all the way to commercialization, and ultimately market acceptance.  We will cover drugs, devices, and diagnostics in the retina space.  I hope to explore in some detail the thoughts of our experts on topics including basic science, clinical trials, team-building, business management, fundraising, career decision-making, and of course, issues around work-life balance. I will be speaking to a group of highly successful, hard-working people, and it will be great to get a sense of who they are and learn a bit about their personal histories.
​​
I would also like to thank my friend and colleague, Craig Simak, Co-Founder of OIS, for entrusting me with the OIS-Retina Podcast, and will do my best to simply stay out of the way while we hear from these amazing leaders and innovators in our field.
Picture
Picture
Picture
Dr. Ehsan Sadri introduces Dr. Rahhal as host of the OIS Retina Podcast. Join them for an invigorating conversation about clinical practice and investing in emerging ophthalmic companies. 
Firas then speaks with his friend, Mark Humayun, the ophthalmologist, innovator, engineer, scientist, academic, inventor, and only ophthalmologist elected to both the U.S. National Academies of Medicine and Engineering.
In his third podcast, Firas speaks with the CEO of ONL Therapeutics, an ExSight portfolio company, about his journey from West Point to CEO of a company on the verge of important therapeutic breakthroughs.  
0 Comments

WALL STREET JOURNAL COVERS NEW CROP OF VENTURE FIRMS INCLUDING EXSIGHT

7/11/2020

0 Comments

 
Picture

New Crop of Venture Firms Takes Aim at Individual Disease Areas
Some venture capitalists are raising funds focused on cancer or other specific medical fields

"Founders of disease-specific funds say it is possible to build a diversified portfolio within a single sector. In ophthalmology, there are distinct diseases affecting the front and back of the eyes, and a variety of drugs and medical devices are being developed to treat them, said James Murray, co-founder and partner of ExSight Ventures, a vision-focused firm based in New York.
“Within one small area of the body, you have the opportunity to invest in different sectors that have different risk profiles,” Mr. Murray said. ​
ExSight Ventures was mentioned alongside other specialized venture firms in an article by Brian Gormley in the Wall Street Journal. 
The article covers the "long-running trend toward specialization in venture capital."
Read the article on WSJ.com. 


0 Comments

    Author

    ExSight Ventures

    Archives

    January 2021
    December 2020
    August 2020
    July 2020
    June 2020
    February 2020
    December 2019
    October 2019
    August 2019
    July 2019
    February 2019
    September 2018
    August 2018
    July 2018

    View my profile on LinkedIn

    Categories

    All

    RSS Feed

 ©ExSight Ventures, LLC                    Privacy Policy                    Terms and Conditions          Disclaimer       
  • Home
  • Companies
  • Team
  • Blog
  • Contact
  • Thesis